Press Releases

Press Releases

    Date Title View
    06/02/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    06/02/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    PDF Version
    06/01/23
    Summary ToggleBiomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)
    PDF Version
    05/31/23
    Summary TogglePresentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
    PDF Version
    05/31/23
    Summary ToggleNew Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
    PDF Version
    05/23/23
    Summary ToggleHorizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
    PDF Version
    05/16/23
    Summary ToggleHorizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
    PDF Version
    05/10/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    PDF Version
    05/09/23
    Summary ToggleHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
    PDF Version
    05/04/23
    Summary ToggleHorizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
    PDF Version
    Displaying 31 - 40 of 786 results